Composition for promoting bone health and bone formation as well as application and product thereof

Abstract

The invention provides a composition for promoting bone health and bone formation as well as application and a product thereof, and belongs to the field of foods. The composition disclosed by the invention is prepared from the following components in parts by weight: 1 to 5 parts of osteopontin, 1 to 50 parts of 2 '-fucosyllactose and 0.05 to 50 parts of a calcium source. The composition disclosed by the invention shows a relatively good synergistic effect in promoting calcium absorption, and can be used for improving bone density, preventing and treating osteoporosis and the like.

Description

Technical Field

[0001] The invention belongs to the field of food, and in particular relates to a composition for promoting calcium absorption and an application and product thereof. Background Art

[0002] Calcium is a mineral required by the human body. Calcium intake plays a key role in maintaining normal bone density, reducing fractures, promoting adolescent development and reducing the risk of osteoporosis in the elderly. Calcium deficiency may be caused by long-term malnutrition, abnormal calcium metabolism and other reasons, and the typical symptoms are different in different periods. Calcium deficiency in infants and children may cause baldness on the back of the head, night sweats, night terrors, late teething, late learning to walk, aversion to milk, indigestion and other problems. If not supplemented in time, it may lead to rickets such as square head, X-shaped legs, O-shaped legs and rib valgus; for adolescents in the growth and development period, calcium deficiency may cause slow height growth, poor tooth development, leg cramps, and other phenomena, and may also cause symptoms such as allergies and colds; in adults and the elderly, calcium deficiency may induce symptoms such as back pain, irritability, limb fatigue, and accompanied by leg cramps, insomnia, and dreaminess; for women during pregnancy and lactation, the demand for calcium is relatively greater. Calcium deficiency may cause loose teeth, leg cramps, pregnancy-induced hypertension, and affect the fetus's absorption of calcium.

[0003] For people who are calcium deficient, they can take in calcium-rich foods such as dairy products, soy products, animal liver, kelp, etc. to alleviate the problems caused by calcium deficiency. However, calcium is not absorbed efficiently after intake, which means that in order to achieve the effect of calcium supplementation, the actual intake must be much higher than the required amount. For raw materials with low calcium content, a larger dose is required to take in the same amount of calcium.

[0004] 2'-fucosyllactose (2'-FL) is an oligosaccharide that is widely present in breast milk and is therefore often used as a food ingredient, especially in infant food. 2'-fucosyllactose has anti-infection, antioxidant, anti-inflammatory effects, improves intestinal flora, and affects the composition of intestinal flora metabolites.

[0005] Osteopontin (OPN) is a glycosylated protein that is widely present in the extracellular matrix. OPN is an important bone matrix protein that is closely related to the formation and development of bones. The content of osteopontin in breast milk is very high (about 138 mg / L on average), and it is an important immunologically active protein in breast milk. Osteopontin in breast milk is also called lactopontin and milk osteopontin. The glycosylation modification of OPN is mainly O-glycan, among which the proportion of sialylation is high, so it can also be called sialoglycoprotein.

[0006] Osteopontin activity can directly reach the intestines, enhance the intestinal protective barrier function, and achieve systemic immune protection. The content of osteopontin in the plasma of newborn umbilical cord blood and 3-month-old infants is very high, about 7-10 times that of adults, indicating that it is closely related to the growth and development of infants in their early life.

[0007] In the prior art, 2'-fucosyllactose and osteopontin are relatively widely used in food. For example, the patent application with application number CN202410402081.1 records that Bifidobacterium longum subspecies longum i772, 2'-fucosyllactose, lactose-N-neotetraose and lutein have a synergistic effect in promoting bone growth and development. The composition can effectively relieve eye cell apoptosis caused by visual fatigue and can be applied to infant formula milk powder, children's formula milk powder, fermented milk and health food; the patent application with application number CN202111219519.5 discloses a composition for promoting growth and development, comprising osteopontin, zinc-rich yeast, optional nutritional components and optional auxiliary materials, and the osteopontin is 0.1-99.9 parts by weight, and the zinc-rich yeast is 0.1-99.9 parts by weight. By using the scientific combination of various raw material components such as osteopontin, zinc-rich yeast, lactoferrin, etc., it has the effect of promoting growth and development and enhancing the body's immunity.

[0008] However, the current existing technology is not perfect for the development of the above ingredients, and there is still a lot of room for optimization. Summary of the invention

[0009] In order to solve the above problems, the present invention provides a composition for promoting bone health and bone formation and its application.

[0010] In one aspect, the present invention provides:

[0011] A composition for promoting bone health and bone formation, comprising 2'-fucosyllactose, osteopontin and a calcium source. The composition comprises 1-5 parts of osteopontin, 1-50 parts of 2'-fucosyllactose and 0.05-50 parts of the calcium source by weight.

[0012] Based on the above range, the amount of each component in the composition can be selected from any combination of the following ranges:

[0013] (1) The osteopontin may be 1-5 parts, 1-2 parts, 1-3 parts, 1-4 parts, 2-3 parts, 2-4 parts, 3-4 parts, 3-5 parts, 2-5 parts, 1.5-3.5 parts, 1.5-2.5 parts, 1.5-4.5 parts, 1.3-3.8 parts, 1.2-4.5 parts,;

[0014] (2) the 2'-fucosyllactose may be 1-50 parts, 1-40 parts, 1-30 parts, 1-20 parts, 1-10 parts, 1-5 parts, 1-8 parts, 5-18 parts, 10-50 parts, 10-40 parts, 10-30 parts, 10-20 parts, 10-15 parts, 16-18 parts, 20-50 parts, 20-40 parts, 20-30 parts, 30-50 parts, 30-40 parts, 30-45 parts, 30-48 parts, 25-45 parts, 35-40 parts, 35-38 parts, 38-40 parts, 35.5-45.5 parts;

[0015] (3) The calcium source can be 0.05-50 parts, 0.05-40 parts, 0.05-30 parts, 0.05-20 parts, 0.05-10 parts, 0.05-50 parts, 1-50 parts, 1-40 parts, 1-30 parts, 1-20 parts, 1-10 parts, 1-5 parts, 1-8 parts, 3-5 parts, 3-10 parts, 3-14 parts, 5-14 parts, 5-50 parts, 5 -40 parts, 5-30 parts, 5-20 parts, 5-10 parts, 10-50 parts, 10-40 parts, 10-30 parts, 10-20 parts, 10-15 parts, 20-50 parts, 20-40 parts, 20-30 parts, 30-50 parts, 30-40 parts, 30-45 parts, 30-48 parts, 25-45 parts, 35-40 parts, 35-38 parts, 38-40 parts.

[0016] Preferably, the composition comprises, by weight, 1 part of osteopontin, 5-18 parts of 2'-fucosyllactose and 3-14 parts of a calcium source.

[0017] Preferably, the composition comprises, by weight, 1 part of osteopontin, 16-18 parts of 2'-fucosyllactose and 3-5 parts of a calcium source.

[0018] Preferably, the composition comprises, by weight, 1 part of osteopontin, 16 parts of 2'-fucosyllactose and 5 parts of calcium source.

[0019] Preferably, the composition comprises, by weight, 1 part of osteopontin, 18 parts of 2'-fucosyllactose and 3 parts of calcium source.

[0020] Preferably, the composition comprises, by weight, 1 part of osteopontin, 5 parts of 2'-fucosyllactose and 14 parts of calcium source.

[0021] The calcium source is selected from any one or more of calcium carbonate, calcium gluconate, calcium citrate, calcium lactate, L-calcium lactate, calcium hydrogen phosphate, calcium L-threonate, calcium glycinate, calcium aspartate, calcium citrate malate, calcium acetate, calcium chloride, tricalcium phosphate, vitamin E calcium succinate, and calcium glycerophosphate.

[0022] The calcium source may be present in the composition independently or in combination with other ingredients, such as a conjugate with casein, a conjugate with a polypeptide, a conjugate with casein phosphopeptide, a conjugate with α-lactoprotein, etc. The content of the calcium source in the composition of the present invention is calculated as the calcium ion content in the conjugate / composition.

[0023] For example, the calcium source of the present invention can be milk mineral salt, and each 1g of milk mineral salt can contain 0.269g of calcium, or as is well known in the art, the calcium content of the milk mineral salt raw material is 23%wt-28%wt.

[0024] For another example, the calcium source can be realized by directly adding a background, and the background includes but is not limited to raw materials such as skim milk, concentrated whey protein, lactose, etc.; or it can also be a combination of these backgrounds and mineral salts. For example, in certain specific products, the source of calcium content in the product can include any one or more of the aforementioned backgrounds and any one or more of calcium carbonate and tricalcium phosphate. In such examples, the actual addition amount of the background or the combination of the background and the mineral salt used to provide the calcium source is higher than the aforementioned calcium source addition amount. A more specific example application can be segmented milk powder. Those skilled in the art can select the calcium source according to actual needs, such as selecting a combination of background and calcium carbonate in 1 or 3 stage milk powder, and selecting a combination of background and calcium carbonate and tricalcium phosphate in 2 stage milk powder. In practical applications, the content of mineral calcium salts may also be limited, such as limiting the proportion of calcium carbonate in the combination of background and mineral salts (for example, the mass proportion is <50%) and other conditions. The adjustments of the raw material form and the amount of raw material added by those skilled in the art without departing from the technical concept of the present invention are all within the scope of protection of the technical solution of the present invention.

[0025] When the calcium source in the composition of the present invention is calcium phosphate, the preferred added weight portion of calcium phosphate is 10-40 parts, and more preferably 12.9-36.2 parts.

[0026] When the calcium source in the composition of the present invention is calcium citrate, the preferred added weight portion of calcium citrate is 10-30 parts, and more preferably 14.3-23.8 parts.

[0027] When the calcium source in the composition of the present invention is calcium carbonate, the preferred added weight portion of calcium carbonate is 5-35 parts, and more preferably 7.5-35 parts.

[0028] Preferably, the calcium source is selected from any one or more of animal milk, seafood, nuts, soy products, and green leafy vegetables.

[0029] The animal milk includes but is not limited to: cow's milk and goat's milk.

[0030] The marine products include but are not limited to: fish, shrimp, crab, and seaweed.

[0031] In another aspect, the present invention provides use of the composition in preparing a calcium supplement product.

[0032] Preferably, the calcium supplement product can be an oral product.

[0033] The efficacy of the calcium supplement product includes but is not limited to: increasing bone density, increasing blood calcium content, increasing bone calcium content, and preventing or treating osteoporosis.

[0034] Based on the above, the present invention also protects the calcium supplement product of the composition.

[0035] According to the general understanding of those skilled in the art, the calcium supplement product may also include food excipients or pharmaceutical excipients.

[0036] The food auxiliary materials include, but are not limited to, any one or more of gelling agents, sweeteners, acidulants, moisture retainers, food flavors, nutritional supplements, thickeners, emulsifiers, and dispersants.

[0037] The pharmaceutical excipients include, but are not limited to, any one or more of fillers, binders, disintegrants, lubricants, emulsifiers, antioxidants, antibacterial agents, isotonicity regulators, suspending agents, solubilizers, cosolvents, preservatives, and flavoring agents.

[0038] The calcium supplement products include, but are not limited to, any one or more of oral liquid, modulated milk powder, jelly candy, hard candy, milk beverage, gluten product, soda, and fruit juice.

[0039] The present invention also provides a general preparation method of a calcium supplement product, comprising mixing the composition with auxiliary materials. Those skilled in the art can adjust the auxiliary material formula and preparation conditions according to specific purposes through conventional preparation methods.

[0040] Beneficial effects of the present invention:

[0041] The present invention provides a composition capable of promoting calcium absorption by compounding effective ingredients. The components have significant synergistic effects and show good effects. The composition has good application value in improving bone density, preventing and treating osteoporosis, etc. DETAILED DESCRIPTION

[0042] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.

[0043] The source information of some raw materials in the examples is as follows:

[0044]

[0045] Those skilled in the art should be aware that the specific source of raw materials can be replaced by conventional means and the purchase channel can be selected according to actual conditions. Therefore, the source of raw materials in the present invention is only shown as an example of a feasible solution and is not used to limit the actual application form of the present invention.

[0046] Example 1

[0047] The invention comprises, by weight, 1 part of osteopontin, 16 parts of 2'-fucosyllactose and 5 parts of calcium source.

[0048] The calcium source in this embodiment is calcium phosphate, wherein the calcium content is calculated as 38.71%, and the actual amount of calcium phosphate used is about 12.9 parts.

[0049] Example 2

[0050] The invention comprises, by weight, 1 part of osteopontin, 18 parts of 2'-fucosyllactose and 3 parts of calcium source.

[0051] The calcium source in this embodiment is calcium citrate, wherein the calcium content is calculated as 24.1%, and the actual amount used is about 12.5 parts.

[0052] Example 3

[0053] The invention comprises, by weight, 1 part of osteopontin, 5 parts of 2'-fucosyllactose and 14 parts of calcium source.

[0054] The calcium source in this embodiment is calcium carbonate, wherein the calcium content is calculated as 40%, and the actual amount used is 35 parts.

[0055] Example 4

[0056] Referring to Example 1, the calcium source was replaced with calcium citrate, and the actual amount used was 20.8 parts.

[0057] Example 5

[0058] Referring to Example 2, the calcium source was replaced with calcium carbonate, and the actual amount used was 7.5 parts.

[0059] Example 6

[0060] Referring to Example 3, the calcium source was replaced with calcium phosphate, and the actual amount used was 36.2 parts.

[0061] Effect Experiment Example 1 Animal Intervention Experiment

[0062] The conventional validation scheme of existing technology is used to conduct animal intervention experiments, which specifically includes the following:

[0063] Experimental animals: 4-week-old male C56BL / 6 mice, weighing (20±2) g, were provided by Shanghai Slake Laboratory Animal Co., Ltd.

[0064] Grouping and feeding: The mice were adaptively fed for one week (temperature 23±2°C, humidity 50±2%, light-dark alternation every 12 hours). After the adaptive feeding was completed, the mice were randomly divided into groups (n=7) and gavaged with the following samples:

[0065] The Example and Comparative Example groups were gavaged with the corresponding composition at a dose of 500 mg / kg per day, and the control group was gavaged with a placebo; the gavage frequency was once a day, at about 10 am every day, for 8 weeks.

[0066] Before oral administration (0w) and after the end of the experiment (8w), the whole-body bone density (BMD, mg / cm 2 ) test, the results are as follows:

[0067] Group 0w 8w Control group 60.3±2.4 61.4±3.1 Example 1 61.1±3.5 <![CDATA[76.5±4.1** ## ]]> Example 2 60.8±2.8 <![CDATA[74.2±2.5** ## ]]> Example 3 62.0±3.7 <![CDATA[70.6±2.3** # ]]> Example 4 61.7±2.0 <![CDATA[75.8±3.9** ## ]]> Example 5 61.9±1.6 <![CDATA[73.9±3.4** ## ]]> Example 6 60.5±1.9 <![CDATA[71.7±4.7** ## ]]>

[0068] Compared with 0w, ** indicates P < 0.01; compared with the control group, # indicates P < 0.05, and ## indicates P < 0.01.

[0069] According to the above data, the compositions of Examples 1-6 significantly increased the bone density of experimental mice at 8 weeks compared with the control group, indicating that they have a certain effect of promoting bone formation. Among them, Examples 1-2 and 4-6 have more significant differences compared with the control group.

[0070] Effect Experiment Example 2 Calcium Deficiency Animal Model Experiment

[0071] A calcium deficiency animal model was constructed with reference to the prior art to verify the calcium supplementation effect of the present invention, as follows:

[0072] Experimental animals: 21-day-old SD rats, weighing 50±5 g, provided by Shanghai Slake Laboratory Animal Co., Ltd.

[0073] Model construction method: The model was constructed by giving low-calcium feed, which refers to feed containing 20 mg of calcium per 100 g.

[0074] The groups were divided into the following groups (n=7):

[0075] Blank control group: fed with normal mouse feed and allowed to drink water freely;

[0076] Model group: fed with low-calcium feed and free access to water;

[0077] Experimental group: The mice were fed with low-calcium feed and allowed to drink water freely. Meanwhile, the corresponding composition in each example was intragastrically administered at a dose of 500 mg / kg per day.

[0078] At the end of the 4th week (4w) and the 6th week (6w) of administration, blood was collected from the hearts of rats in each group, and the blood calcium content (mM) was measured using a commercially available calcium detection kit.

[0079] After blood was collected at 8 weeks of administration, the whole-body bone density (BMD, mg / cm 2 ) detection; rat femurs were taken for bone calcium (mg / g) determination.

[0080] The determination of rat bone calcium is completed by EDTA titration of femoral ash with reference to the existing technology, which specifically includes: after the femur is ashed, 0.05g of bone ash sample is weighed, 1mL of 6mol / L HCl is added to dissolve it, and then 20mL of pure water is added. After adding 2mL of 2mol / L NaOH to adjust to neutrality, 50μL of 10g / L KCN and 100μL of 0.05mol / L sodium citrate are added. After shaking well, add 2mL of NaOH and 1-2 drops of calcium red indicator, and titrate with 0.01mol / L EDTA until the red turns to pure blue, which is the end point. The change of bone calcium is characterized by the proportion of bone calcium content in femoral ash, and the calculation method is as follows:

[0081] Bone calcium content (mg / g) = V1×C1×40×1000 / M1;

[0082] Among them, V1 is the amount of EDTA used for titration, in mL; C1 is the concentration of EDTA solution, in mol / L; M1 is the sampling amount of bone ash sample for titration, in g.

[0083] Result data:

[0084] (1) The results of blood calcium (mM) are as follows:

[0085] Group 4w 6w 8w Blank control group <![CDATA[2.48±0.14 ## ]]> <![CDATA[2.51±0.11 ### ]]> <![CDATA[2.49±0.07 ### ]]> Model Group 2.13±0.09** 1.95±0.13*** 1.24±0.15*** Example 1 <![CDATA[2.52±0.14 ## ]]> <![CDATA[2.58±0.12 ### ]]> <![CDATA[2.53±0.05 ### ]]> Example 2 <![CDATA[2.47±0.16 ## ]]> <![CDATA[2.45±0.17 ### ]]> <![CDATA[2.39±0.04 ### ]]> Example 3 <![CDATA[2.45±0.08 ## ]]> <![CDATA[2.47±0.12 ### ]]> <![CDATA[2.34±0.23 ### ]]> Example 4 <![CDATA[2.50±0.11 ## ]]> <![CDATA[2.44±0.20 ### ]]> <![CDATA[2.46±0.11 ### ]]> Example 5 <![CDATA[2.39±0.15 ## ]]> <![CDATA[2.36±0.07 ### ]]> <![CDATA[2.45±0.14 ### ]]> Example 6 <![CDATA[2.43±0.17 ## ]]> <![CDATA[2.34±0.24 ### ]]> <![CDATA[2.40±0.18 ### ]]>

[0086] Among them, compared with the blank control group, ** indicates P < 0.01, *** indicates P < 0.001; compared with the model group, ## indicates P < 0.01, ### indicates P < 0.001.

[0087] The above data show that the blood calcium concentration in the model group is reduced, and the composition of Examples 1-6 can restore the reduction of blood calcium caused by a low-calcium diet.

[0088] (2) Bone mineral density (BMD, mg / cm 2 ) The results are as follows:

[0089] Group 8w Blank control group <![CDATA[66.3±2.6 ## ]]> Model Group 51.4±3.1** Example 1 <![CDATA[79.4±3.5** ### ]]> Example 2 <![CDATA[78.2±1.6** ### ]]> Example 3 <![CDATA[73.5±1.8* ### ]]> Example 4 <![CDATA[78.8±2.4** ### ]]> Example 5 <![CDATA[77.9±2.1** ### ]]> Example 6 <![CDATA[76.7±3.7** ### ]]>

[0090] Among them, compared with the blank control group, ** indicates P < 0.01; compared with the model group, ## indicates P < 0.01, and ### indicates P < 0.001.

[0091] It can be seen from the above data that the compositions of Examples 1-6 can not only alleviate the decrease in bone density caused by calcium deficiency, but also further promote bone development and increase bone density.

[0092] (3) The results of bone calcium (mg / g) are as follows:

[0093] Group 8w Blank control group <![CDATA[187.5±18.7 ## ]]> Model Group 138.6±22.4** Example 1 <![CDATA[198.4±13.2 ## ]]> Example 2 <![CDATA[192.7±15.6 ## ]]> Example 3 <![CDATA[189.5±18.4 ## ]]> Example 4 <![CDATA[191.3±17.1 ## ]]> Example 5 <![CDATA[192.1±20.6 ## ]]> Example 6 <![CDATA[186.4±16.4 ## ]]>

[0094] Among them, ** indicates P < 0.01 compared with the blank control group; ## indicates P < 0.01 compared with the model group.

[0095] According to the bone calcium determination results, it can be seen that the composition of the present invention can alleviate the problem of decreased bone calcium content in the model group.

[0096] In summary, the compositions in the embodiments of the present invention can achieve a good effect of promoting calcium absorption and relieve calcium deficiency symptoms. In order to better reflect the effect of the present invention, the present invention also verifies the effect of the following comparative examples:

[0097] Comparative Example 1

[0098] A composition comprises, by weight, 1 part of osteopontin, 16 parts of oligofructose and 5 parts of a calcium source, wherein the calcium source is calcium phosphate.

[0099] Comparative Example 2

[0100] A composition comprises, by weight, 1 part of lactoferrin, 16 parts of 2'-fucosyllactose and 5 parts of a calcium source, wherein the calcium source is calcium phosphate.

[0101] Comparative Example 3

[0102] A composition comprises, by weight, 16 parts of 2'-fucosyllactose and 5 parts of a calcium source, wherein the calcium source is calcium phosphate.

[0103] Comparative Example 4

[0104] A composition comprises, by weight, 1 part of osteopontin and 5 parts of a calcium source, wherein the calcium source is calcium phosphate.

[0105] Comparative Example 5

[0106] A composition comprises, by weight, 16 parts of osteopontin, 1 part of 2'-fucosyllactose and 5 parts of a calcium source, wherein the calcium source is calcium phosphate.

[0107] Comparative Example 6

[0108] A single calcium source (calcium phosphate) was used as Comparative Example 6.

[0109] The comparative example was verified with reference to the effect experimental example 1-2 (conducted simultaneously with the example, using the same blank control group and model group). It should be noted that when gavage was performed according to the formula of the comparative example, due to the lack of ingredients in comparative example 3-4, the actual gavage amount ensured that each individual ingredient was consistent with the gavage amount of Example 1, rather than the overall total amount.

[0110] Bone mineral density (BMD, mg / cm 2 ) The test results are as follows:

[0111] Group 0w 8w Comparative Example 1 61.5±0.16 <![CDATA[67.7±0.14 **##AA ]]> Comparative Example 2 61.4±0.08 <![CDATA[68.5±0.21 **##AA ]]> Comparative Example 3 61.8±0.13 <![CDATA[63.9±0.15 *#AA ]]> Comparative Example 4 62.1±0.04 <![CDATA[65.2±0.06 *#AA ]]> Comparative Example 5 61.7±0.23 <![CDATA[63.4±0.16 *#AA ]]> Comparative Example 6 61.2±0.15 <![CDATA[61.3±0.07 AA ]]>

[0112] Compared with 0w, * indicates P < 0.05, ** indicates P < 0.01; compared with the control group, # indicates P < 0.05, ## indicates P < 0.01; compared with Example 1, AA indicates P < 0.01.

[0113] It can be seen that in the animal intervention experiment, the effect data of Comparative Examples 1-6 are all worse than that of Example 1, and to a certain extent reflect the synergistic effect of the components in the composition of Example 1.

[0114] The results of the calcium deficiency animal model experiment are as follows:

[0115] (1) The results of blood calcium (mM) are as follows:

[0116] Group 4w 6w 8w Comparative Example 1 <![CDATA[2.38±0.14 ## ]]> <![CDATA[2.39±0.28 ### ]]> <![CDATA[2.44±0.25 ### ]]> Comparative Example 2 <![CDATA[2.41±0.26 ## ]]> <![CDATA[2.46±0.15 ### ]]> <![CDATA[2.41±0.17 ### <!-- 7 -->]]> Comparative Example 3 <![CDATA[2.39±0.31 ## ]]> <![CDATA[2.44±0.04 ### ]]> <![CDATA[2.51±0.25 ### ]]> Comparative Example 4 <![CDATA[2.51±0.02 ## ]]> <![CDATA[2.53±0.06 ### ]]> <![CDATA[2.49±0.14 ### ]]> Comparative Example 5 <![CDATA[2.50±0.17 ## ]]> <![CDATA[2.32±0.14 ### ]]> <![CDATA[2.31±0.07 ### ]]> Comparative Example 6 2.42±0.24 <![CDATA[2.51±0.15 ### ]]> <![CDATA[2.39±0.22 ### ]]>

[0117] Among them, ## indicates P < 0.01, and ### indicates P < 0.001 compared with the model group.

[0118] The compositions in Comparative Examples 1-6 also showed an increase in blood calcium content in the calcium-deficient rat model, with significant differences compared to the model group, and the overall level was roughly the same as that in Example 1.

[0119] (2) Bone mineral density (BMD, mg / cm 2 ) The results are as follows:

[0120] Comparative Example 8w Comparative Example 1 <![CDATA[65.1±2.2 ##AA ]]> Comparative Example 2 <![CDATA[62.4±3.4 ##AA ]]> Comparative Example 3 <![CDATA[61.8±0.6 #AA ]]> Comparative Example 4 <![CDATA[60.3±1.7 #AA ]]> Comparative Example 5 <![CDATA[64.8±2.5 ##AA ]]> Comparative Example 6 <![CDATA[53.7±1.9 AAA ]]>

[0121] Compared with the model group, # indicates P < 0.05, and ## indicates P < 0.01; compared with Example 1, AA indicates P < 0.01, and AAA indicates P < 0.001.

[0122] It can be seen from the above that the composition of the comparative example can also alleviate the bone density of calcium-deficient rats to a certain extent, but the effect is significantly worse than that of Example 1.

[0123] (3) The results of bone calcium (mg / g) are as follows:

[0124] Comparative Example 8w Comparative Example 1 <![CDATA[161.4±12.0 #AA ]]> Comparative Example 2 <![CDATA[165.2±18.6 #AA ]]> Comparative Example 3 <![CDATA[156.8±15.4 #AA ]]> Comparative Example 4 <![CDATA[157.6±16.1 #AA ]]> Comparative Example 5 <![CDATA[158.1±13.8 #AA ]]> Comparative Example 6 <![CDATA[152.9±10.7 #AA ]]>

[0125] Wherein, compared with the model group, # indicates P < 0.05; compared with Example 1, AA indicates P < 0.01.

[0126] According to the bone calcium data, it can be seen that the composition of the comparative example is far inferior to Example 1 in alleviating the bone calcium content in the rat model.

[0127] In summary, it can be seen that the components in the present invention have a significant synergistic effect in alleviating the calcium deficiency symptoms of the calcium deficiency rat model, especially in improving bone density, and have unexpected technical effects.

[0128] Application Example 1 A gel candy for promoting calcium absorption

[0129] The composition comprises any one of embodiments 1-6, and also comprises commonly used gel candy auxiliary materials: gelling agent, sweetener, acidulant, moisture retaining agent, food flavoring and the like.

[0130] The gel candy provided in this application example has high consumer acceptance, especially for children with high calcium supplementation needs, and has a good effect of promoting calcium absorption and bone development.

[0131] Application Example 2 A powder for promoting calcium absorption

[0132] The invention comprises any one of the compositions of embodiments 1 to 6, and further comprises other auxiliary materials of the modulated powder: concentrated whey protein powder, skim milk powder, whole milk powder, galacto-oligosaccharide, etc. The modulated powder is prepared by referring to the conventional preparation method of the prior art, and the modulated powder can be modulated milk powder or modulated protein powder. The obtained modulated powder has a good ability to promote calcium absorption, and is suitable for infants, the elderly and other people who need calcium supplementation.

[0133] Application Example 3 An oral solution for promoting calcium absorption

[0134] The composition comprises any one of embodiments 1-6, and further comprises oral liquid auxiliary materials: maltitol liquid, xylitol, corn oil, gum arabic, citric acid, xanthan gum, flavor, and purified water.

[0135] The oral liquid is easy to take, tastes good, is widely accepted by the public, and can promote calcium absorption.

[0136] The above embodiments and application embodiments are only used to illustrate the present invention and are presented as some examples. They do not have the effect of limiting the present invention. The technical solutions obtained by the adjustment, substitution and optimization of conventional technical means carried out by those skilled in the art without departing from the technical concept of the present invention are still within the scope of protection of the present invention.

Claims

1. A composition for promoting bone health and bone formation, characterized in that: The composition is composed of 2'-fucosyllactose, osteopontin and a calcium source. In the composition, the osteopontin is 1-5 parts, the 2'-fucosyllactose is 1-50 parts and the calcium source is 0.05-50 parts by weight.

2. The composition according to claim 1, characterized in that The composition comprises, by weight, 1 part of osteopontin, 5-18 parts of 2'-fucosyllactose and 3-14 parts of a calcium source.

3. The composition according to claim 2, characterized in that The composition comprises, by weight, 1 part of osteopontin, 16-18 parts of 2'-fucosyllactose and 3-5 parts of a calcium source.

4. The composition according to claim 1, characterized in that The calcium source is selected from any one or more of calcium carbonate, calcium gluconate, calcium citrate, calcium lactate, L-calcium lactate, calcium hydrogen phosphate, calcium L-threonate, calcium glycinate, calcium aspartate, calcium citrate malate, calcium acetate, calcium chloride, tricalcium phosphate, vitamin E calcium succinate, and calcium glycerophosphate.

5. The composition according to claim 4, characterized in that The calcium source is selected from any one or more of animal milk, seafood, nuts, soy products, and green leafy vegetables.

6. Use of the composition according to any one of claims 1 to 5 in the preparation of calcium supplement products.

7. The use according to claim 6, characterized in that: The calcium supplement product is an oral product.

8. The use according to claim 7, characterized in that: The efficacy of the calcium supplement product includes: increasing bone density, increasing blood calcium content, increasing bone calcium content, and preventing or treating osteoporosis.

9. A calcium supplement product comprising the composition according to any one of claims 1 to 5.

10. The calcium supplement product according to claim 9, characterized in that: The calcium supplement product also includes food supplements or pharmaceutical supplements.

11. The calcium supplement product according to claim 10, characterized in that: The food auxiliary material is selected from any one or more of: gelling agent, sweetener, acidulant, moisture retaining agent, food flavor, nutritional supplement, thickener, emulsifier and dispersant.

12. The calcium supplement product according to claim 10, characterized in that: The pharmaceutical excipients are selected from any one or more of fillers, binders, disintegrants, lubricants, emulsifiers, antioxidants, antibacterial agents, isotonicity regulators, suspending agents, solubilizers, cosolvents, preservatives, and flavoring agents.

13. The calcium supplement product according to claim 9, characterized in that: The calcium supplement product is selected from any one or more of oral liquid, modulated milk powder, gel candy, hard candy, milk beverage, gluten product, soda and fruit juice.

14. A method for preparing a calcium supplement product, characterized in that: The method comprises mixing the composition of claim 1 with auxiliary materials.

Images